Comparisons of Cytokines, Growth Factors and Clinical Efficacy between Platelet-Rich Plasma and Autologous Conditioned Serum for Knee Osteoarthritis Management

Biomolecules. 2023 Mar 17;13(3):555. doi: 10.3390/biom13030555.

Abstract

This study aimed to directly compare the contents and the clinical efficacy of the two autologous blood-derived products, platelet-rich plasma (PRP) and autologous conditioned serum (ACS) for osteoarthritis (OA) treatment. The contents of standard-prepared PRP and ACS prepared at 37 °C for 1 h, 3 h, 6 h, and 24 h from healthy volunteers were compared. The clinical efficacy of pain relief in patients with Stage III knee OA was evaluated by a patient-reported visual analog scale (VAS) pain rating. PDGF-BB levels in ACS 1 h were significantly higher than those in PRP, and the levels in ACS preparations remained stable. IGF-1 level of ACS 24 h showed a significant increase compared to those of other ACS preparations and PRP. ACS 3 h showed a turning of IL-1Ra level and revealed a time-dependent increase up to 24 h. ACS 6 h showed a turning increase in TNF-α levels. ACS 3 h was chosen for clinical comparison with PRP. The reduction in pain VAS in the ACS group was significantly more compared to those of the PRP group (p = 0.028). However, PRP showed significant earlier improvement (p < 0.001). Conclusion: ACS contained higher levels of PDGF-BB and IL-1Ra and provided better improvement in pain relief compared to PRP.

Keywords: autologous conditioned serum; intra-articular injections; knee; osteoarthritis; platelet-rich plasma.

MeSH terms

  • Becaplermin / metabolism
  • Cytokines / metabolism
  • Humans
  • Intercellular Signaling Peptides and Proteins / metabolism
  • Interleukin 1 Receptor Antagonist Protein / metabolism
  • Osteoarthritis, Knee* / metabolism
  • Osteoarthritis, Knee* / therapy
  • Pain / metabolism
  • Platelet-Rich Plasma* / metabolism
  • Treatment Outcome

Substances

  • Cytokines
  • Interleukin 1 Receptor Antagonist Protein
  • Becaplermin
  • Intercellular Signaling Peptides and Proteins

Grants and funding

This research received no external funding.